Info about patent attorney defending CNCE in IPR with INCY. Seems qualified and out of the NYC office:
Cynthia Lambert Hardman, a partner in Goodwin's IP Litigation group and chair of the firm’s PTAB practice, is a go-to patent litigator for complex patent cases in U.S. district courts, the U.S. International Trade Commission (ITC), and the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB).
Ms. Hardman represents clients in the pharmaceutical, biosimilar, medical device, nutritional supplement, and consumer product industries. She has deep experience in ANDA cases under the Hatch-Waxman Act and in inter partes reviews (IPRs), having appeared in over 30 pharma and biosimilars-related IPRs. She also litigates cases involving a wide range of other technologies and products such as spinal fixation devices, home pregnancy tests, and video content analysis systems and software.
Ms. Hardman's practice also extends to pre-litigation counseling, including rendering opinions on to patentability, infringement, validity and freedom-to-operate issues.
Ms. Hardman co-founded and co-authors Goodwin’s PTAB newsletter, The PTAB Trial Tracker, which analyzes PTAB, district court, and Federal Circuit decisions that impact post-grant review proceedings. Ms. Hardman is also an editor and regular contributor to the firm’s biosimilars blog, Big Molecule Watch. Ms. Hardman is also an active participant in the firm’s Cannabis practice.
Ms. Hardman has been cited by IAM Patent 1000 – The World’s Leading Patent Practitioners for her “sterling efforts” leading Goodwin’s PTAB practice.
Recent PTAB victories include:
- Achieved victory for IPR petitioner on patent to a method of using an anti-cancer biologic. The decision helps clear our client's path to launching a biosimilar.
- Achieved victory for patent owner in IPRs involving patents on a novel drug dosing regimen. The decisions help protect our client's innovative drug.
- Achieved victory for IPR petitioner on patents to methods of using a nitrogen-scavenging drug. The decisions help clear our client's path to launching a generic drug.